Business Development & Valorization
Turn knowledge into value
-
At RegMed XB, we actively work to transform platforms, enabling technologies, and novel therapies into viable businesses. We do this by licensing them to — and collaborating with — existing companies or promising start-ups.
Valorization: Bringing Research to the Market
RegMed XB empowers researchers to translate scientific discoveries into real-world applications. Whether guiding academic projects or supporting the launch of spin-off companies, we offer the tools, resources, and expertise needed to bring regenerative medicine innovations to the market.
Transforming breakthrough research into practical solutions is challenging. Sometimes, founding a spin-off is the most effective way forward. That’s where we come in, offering:
- Expert advice
- Access to an extensive innovation network
- Financial support through innovation vouchers
Our Valorization Services support you at every stage of the journey — from evaluating your start-up idea to navigating the complexities of the regenerative medicine landscape.
-
Read inspiring success stories:
From serendipity to startup: the story behind SBMatrices
What began as an accidental discovery in a chemistry lab has evolved into a deeptech venture with the potential to significantly impact organoid research and regenerative medicine.
read more
XS Innovations bringing a new standard to dialysis care
XS Innovations is tackling a major challenge for people with end-stage kidney disease: keeping their blood vessel access open for dialysis. Most patients need a special connection between an artery and a vein in their arm, called an arteriovenous fistula (AVF), to ensure enough blood flows during treatment.
read more
Hello R&D sets out to eliminate liver toxicity
Liver toxicity is the number one reason for drugs to be retracted from the market. More reliable methods for predicting drug- induced liver toxicity will not only save drug development costs by detecting liver toxic drugs earlier, but will also spare patients from potential severe side effects due to liver toxicity.
read more
Phlox Therapeutics, is developing RNA-based therapies for genetic cardiomyopathies
Phlox Therapeutics, is developing RNA-based therapies for genetic cardiomyopathies. Founded by Prof. Dr. Eva van Rooij and Prof. Dr. Yigal Pinto in 2022, the company has made significant progress with Dr. Margien Boels, PhD, as Chief Operating Officer.
read more
